scholarly journals Thyroid-Associated Ophthalmopathy after Radioactive Iodine Therapy for Metastatic Follicular Thyroid Carcinoma

2021 ◽  
Vol 2021 ◽  
pp. 1-4
Author(s):  
Daisuke Murayama ◽  
Soji Toda ◽  
Yoichiro Okubo ◽  
Hiroyuki Hayashi ◽  
Ai Matsui ◽  
...  
Keyword(s):  
Connective Tissue ◽  
Thyroid Carcinoma ◽  
Radioactive Iodine ◽  
Follicular Thyroid Carcinoma ◽  
Extraocular Muscles ◽  
Radioactive Iodine Therapy ◽  
Thyroid Associated Ophthalmopathy ◽  
Common Antigens

Thyroid-associated ophthalmopathy (TAO) is an inflammation of the extraocular muscles and periorbital connective tissue caused by autoantibodies against common antigens to both the thyroid and orbit. The release of antigens and induction of hypothyroidism caused by radioactive iodine (RAI) therapy may exacerbate TAO. Here, we present the case of a 67-year-old-woman treated with RAI therapy for metastatic follicular thyroid carcinoma who presented with TAO during the course of sorafenib administration. Tg and TgAb levels were gradually decreased with sorafenib and lenvatinib treatment, and TAO was improved without any ophthalmologic treatment.

scholarly journals Radioactive iodine therapy as single modality treatment in tumor thrombus arising from follicular thyroid carcinoma

2020 ◽  
pp. jnmt.120.247122
Author(s):  
Anwin Joseph Kavanal ◽  
Deepa Singh ◽  
Ashwani Sood ◽  
Sarath B Kumar ◽  
Swayamjeet Satapathy ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Tumor Thrombus ◽  
Radioactive Iodine ◽  
Follicular Thyroid Carcinoma ◽  
Radioactive Iodine Therapy ◽  
Single Modality

scholarly journals Recurrent Hurthle cell thyroid carcinoma does not preclude long-term survival: a case report and review of the literature

2021 ◽  
Vol 15 (1) ◽  
Author(s):  
Richard David Blossey ◽  
Dennis Kleine-Döpke ◽  
Kristina Imeen Ringe ◽  
Daniel Pöhnert ◽  
Bastian Ringe ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Radioactive Iodine ◽  
Follicular Thyroid Carcinoma ◽  
Tumor Biology ◽  
World Health ◽  
Radioactive Iodine Therapy ◽  
Term Survival ◽  
Long Term Survival ◽  
Hürthle Cell

Abstract Background Follicular thyroid carcinoma is the second most common malignancy of the thyroid gland. In 2016, the so-called Hurthle cell thyroid carcinoma, formerly known as the oxyphilic variant of the follicular thyroid carcinoma, was reclassified by the World Health Organization as a separate pathological entity, which accounts for approximately 3% of all thyroid cancers. Although Hurthle cell thyroid carcinomas are known for their more aggressive tumor biology, metastases are observed in a minority of cases, and long-term survival can be expected. However, disseminated disease is often associated with poor outcome. Case presentation In the presented case, a 63-year-old Caucasian female was incidentally diagnosed with Hurthle cell thyroid carcinoma after undergoing hemithyroidectomy for a nodular goiter. Following completion thyroidectomy, two courses of radioactive iodine therapy were administered. After 4 years of uneventful follow-up, the patient gradually developed metastases in five different organs, with the majority representing unusual sites, such as heart, kidney, and pancreas over a course of 14 years. The lesions were either treated with radioactive iodine therapy or removed surgically, depending on iodine avidity. Conclusion Follicular and Hurthle cell thyroid carcinoma are known to potentially spread hematogenously to typical sites, such as lung or bones, however; unusual metastatic sites as presented in our case can also be observed. A search of the literature revealed only scattered reports on patients with multiple metastases in unusual locations. Furthermore, the observed long-term survival of our patient is contradictory to the existing data. As demonstrated, recurrent disease may appear years after the initial diagnosis, emphasizing the importance of consistent aftercare. Radioactive iodine therapy, extracorporeal radiation therapy, and surgical metastasectomy are central therapeutic components. In summary, our case exemplifies that thorough aftercare and aggressive treatment enables long-term survival even in recurrent Hurthle cell thyroid carcinoma displaying unusual multisite metastases.

scholarly journals Anaplastic Thyroid Carcinoma Following Radioactive Iodine Therapy for Graves' Disease

2013 ◽  
Vol 28 (1) ◽  
pp. 61 ◽  
Author(s):  
Sun Hwa Kim ◽  
Hee Young Kim ◽  
Kwang Yoon Jung ◽  
Dong Seop Choi ◽  
Sin Gon Kim
Keyword(s):  
Thyroid Carcinoma ◽  
Radioactive Iodine ◽  
Anaplastic Thyroid Carcinoma ◽  
Graves Disease ◽  
Radioactive Iodine Therapy
Sign in / Sign up

Export Citation Format

Share Document